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Bronchial asthmaAbstract Background: High sensitive C-reactive protein (hs-CRP) and eosinophilic cationic pro-
tein (ECP) have been shown to be associated with asthma in recent studies. However, the relation-
ship between hs-CRP and the control of asthma has not been clearly identiﬁed yet.
Patients and methods: Thirty patients with newly-diagnosed bronchial asthma and 20 healthy
individuals were enrolled in this study. In addition to medical history and physical examination,
asthma was assessed according to the Global Initiative for Asthma (GINA) guidelines. Respiratory
function tests (RFT), serum hs-CRP and ECP levels, serum total IgE levels, circulating eosinophil
count (CE) and asthma control test (ACT) were performed for all subjects.
Results: Serum ECP, serum hs-CRP, serum total IgE and CE were signiﬁcantly higher (p< 0.01,
0.01, 0.05 and 0.05, respectively), while forced expiratory volume in 1 s (FEV1 %) and ACT were
signiﬁcantly lower (p< 0.05) in asthmatic patients compared to the control group. In all patients
with bronchial asthma, serum levels of hs-CRP and ECP showed signiﬁcant positive correlations
with asthma severity (hs-CRP, rs = 0.59, p< 0.01; ECP, rs = 0.63, p< 0.01, respectively) but,
signiﬁcant negative correlations with ACT (hs-CRP, rs = 0.53, p< 0.05; ECP, rs = 0.62,
p< 0.01, respectively) and FEV1 % (hs-CRP, rs = 0.46, p< 0.05; ECP, rs = 0.57, p< 0.01,
respectively). Serum ECP and hs-CRP levels showed signiﬁcant fall (p< 0.01and p< 0.05,
respectively), while, FEV1 % and ACT showed signiﬁcant increase (p< 0.05) in asthmatic patients
who were followed up after 2 months of therapy.
766 A.E. Sileem et al.Conclusion: Coupling measurements of serum levels of both ECP and hs-CRP may add a beneﬁt
in determining the severity and monitoring of the control of bronchial asthma.
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The C-reactive protein (CRP) is an exquisitely sensitive non-
speciﬁc marker of acute inﬂammation and tissue damage [1].
Standard assays for CRP lack the sensitivity needed to deter-
mine the levels of inﬂammation, and thus, recent improve-
ments have resulted in a new generation of highly sensitive
assays. CRP determined using a highly sensitive assay is
referred to as high sensitivity-CRP (hs-CRP). Using hs-CRP,
assessment of conditions indicative of chronic, low-grade
inﬂammation is now possible. It has been demonstrated that
hs-CRP is a strong independent predictor of future myocardial
infarction, stroke, peripheral arterial disease and sudden car-
diac death among healthy men and women, and recurrent
events and death in patients with acute or stable coronary syn-
dromes [2]. Also, low-level inﬂammation, as indicated by
increased hs-CRP serum concentrations, has been described
in both chronic obstructive pulmonary lung diseases (COPD)
and asthma [3]. In asthma, not only local but also systemic
inﬂammation occurs and hs-CRP may play a role in the path-
ogenesis of asthma [4].
Activated eosinophils play an important role in the patho-
genesis of bronchial asthma. Eosinophils may contribute to
airway hyper-responsiveness in asthma through the effects of
eosinophil derived granular proteins on the bronchial epithe-
lium [5]. Of these, is the eosinophilic cationic protein (ECP),
which is largely responsible for the damage associated with
eosinophil inﬁltration in bronchial mucosa [6].
Measuring of serum ECP levels has the advantages over
eosinophil count as, it reﬂects not only the number of cells
but also their degree of activation and therefore a better inﬂam-
matory marker [7]. Serum ECP levels are helpful in determining
asthma activity and deciding the use of antiasthmatic drugs [8].
High serum ECP level may be a predictor and a risk factor for
asthma exacerbation, thus it may have a useful role to play as a
control parameter in asthma guideline [9].
The above mentioned data support the possible role of
serum hs-CRP and ECP as inﬂammatory markers in bronchial
asthma patients. However, the association between serum lev-
els of hs-CRP and ECP and the degree of asthma control and
the relationship between these levels and asthma severity have
not been clearly identiﬁed yet. Hence, this study was carried
out to investigate the association of serum levels of hs-CRP
and ECP with the degree of asthma control, revealed by
asthma control test (ACT), and to compare their levels among
adults with mild, moderate and severe stable asthma.
Patients and methods
Patients
Thirty patients with, newly diagnosed, bronchial asthma (10
mild, 10 moderate and 10 severe) and 20 healthy non smokercontrols were recruited randomly from the Pulmonary Outpa-
tient Clinic between March 2013 and February 2014 in the Al-
Adwani general hospital in Taif, Saudi Arabia. The diagnosis
of asthma and the assessment of severity were performed
according to the Global Initiative for Asthma (GINA) guide-
lines [10], supported by the presence of a clinical diagnosis of
asthma (e.g. recurrent episodes of wheezing, breathlessness
,chest tightness, and coughing, particularly at night or in the
early morning) and spirometric values showing reversibility
of more than and/or equal to 12% in forced expiratory volume
in 1 s (FEV1), or at least 200 mL from baseline after inhalation
of salbutamol (4 · 100 mcg) given by metered dose inhaler
using a spacer device or peak expiratory ﬂow (PEF) variability
P20%.
Asthmatic patients were classiﬁed according to the GINA
guidelines [10] (based on the level of symptoms, airﬂow limita-
tion and lung function variability) into 3 subgroups: mild
asthma (group I, n= 10); moderate asthma (group II,
n= 10) and severe asthma (group III, n= 10).
A total of 15 asthmatic patients (5 out of each asthmatic
subgroup i.e. 5 mild, 5 moderate and 5 severe) were followed
up after 2 months of asthma therapy.
We excluded smokers, patients younger than 18 years,
patients whose body mass index (BMI) was P25 kg/m2,
patients who had an exacerbation of asthma or respiratory
tract infection during the last three months prior to enrollment
and patients with hepatic; renal; cardiovascular diseases; dia-
betes mellitus; cancer or systemic inﬂammatory disorders.
Written informed consents were obtained from all subjects.
Methods
All patients underwent a detailed symptom inquiry, physical
examination and investigations including complete blood
count (including circulating eosinophil (CE) count) , chest
radiograph (postero-anterior view), pulmonary function test
(PFT), serum total Immunoglobulin-E (IgE), serum hs-CRP,
serum ECP and skin prick test (SPT). Also, assessment of
asthma control test (ACT) and body mass index (BMI) was
carried out for all subjects. Elevated serum total IgE level
and positive SPT were used to deﬁne the atopic status.
PFT, ACT, CE and serum levels of total IgE, hs-CRP and
ECP were reassessed for 15 asthmatic patients (5 out of each
asthmatic subgroup) after 2 months of therapy to follow up
the effectiveness of the treatment. Treatment of bronchial
asthma was given according to the GINA guidelines [10].
Measurement of serum hs-CRP
Serum hs-CRP levels were measured using an available high
sensitive-CRP commercial kit (ROCHE Diagnostics’, COBAS
C 501 auto analyzer, Germany). The measurement method
used is based on a particle enhanced immunonephelometry
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measurement.
Measurement of serum ECP
Serum ECP levels were measured by the sandwich ELISA
method using a commercially available test kit (MBL MESA-
CUP ECP ELISA kit, Japan).
Measurement of serum total IgE
Serum total IgE levels were measured by the sandwich ELISA
method using a commercially available test kit (cobas e 411
Germany).
Pulmonary function test
Spirometric PFT, with reversibility testing after inhalation of
salbutamol (4 · 100 mcg) given by metered dose inhaler using
a spacer device, was done using Sensor Medicus 2450 comput-
erized pulmonary function apparatus. Forced vital capacity
(FVC) and forced expiratory volume in 1 s (FEV1) were mea-
sured. The best value of three maneuvers was expressed as a
percentage of the predicted value and as absolute value.
Body mass index
Body mass index (BMI) was calculated as weight in kilograms
divided by the square of height in meters (kg/m2).
Skin prick test
Skin prick test was conducted with a panel of common aeroal-
lergen extracts in the presence of a positive histamine control
and a negative saline control on the forearm. Sixteen aeroaller-
gens were utilized. The test was considered positive if the wheal
was greater than 3 mm in mean diameter.
Asthma control test
ACT [11] was used to evaluate asthma control. The ACT ques-
tionnaire is a validated self-administered questionnaire includ-
ing ﬁve questions related to the last four weeks: Episodes of
breathlessness, nocturnal awakenings, limitations of daily
activities, need for rescue medication and patient’s self-rating
of asthma control. Each question includes ﬁve response modal-
ities with a score ranging from one to ﬁve by increasing level of
asthma control, so the global arithmetic score ranges from ﬁve
to twenty-ﬁve. Well controlled asthma by ACT was deﬁned by
a score P20.
Statistical analysis
Statistical analysis was performed with the SPSS version 19 sta-
tistical software package (SPSS Inc., Chicago, IL, USA). Data
are presented as mean ± SD or median and interquartile range
(IQR). Student’s t test was used for comparison between para-
metric data and Wilcoxon’s rank sum test for non parametric
data. Correlation analysis was carried out using Spearman’s
rank correlation test.P value < 0.05was considered signiﬁcant.Results
Table 1 shows that serum ECP, serum hs-CRP, serum total
IgE and CE were signiﬁcantly higher (p< 0.01, 0.01, 0.05
and 0.05, respectively), while FEV1 % and ACT were signiﬁ-
cantly lower (p< 0.01) in asthmatic patients compared to
the control group.
Table 2 shows the comparative statistics for hs-CRP among
different studied groups. Serum hs-CRP levels were signiﬁ-
cantly higher in all asthmatic patients, group I (mild asthma),
group II (moderate asthma) and group III (severe asthma)
compared to the control group (p< 0.01, 0.05, 0.01 and
0.01, respectively). In addition, serum hs-CRP levels were sig-
niﬁcantly higher in group III compared to group I and group
II (p< 0.01) and in group II compared to group I (p< 0.05).
Table 3 shows the comparative statistics for serum ECP
among different studied groups. Serum ECP levels were signif-
icantly higher in all asthmatic patients, group I, group II and
group III compared to the control group (p< 0.01, 0.05,
0.05 and 0.01, respectively). Moreover, serum ECP levels were
signiﬁcantly higher in group III compared to group I and
group II and in group II compared to group I (p< 0.01,
respectively).
Table 4 shows correlation analysis of serum levels of
hs-CRP and ECP against different studied parameters in all
asthmatic patients. A signiﬁcant positive correlation was
noticed between serum levels of hs-CRP and ECP in asthmatic
patients (rs = 0.67, p< 0.01). Also, in all patients with
bronchial asthma, serum levels of hs-CRP and ECP showed
signiﬁcant positive correlations with asthma severity (hs-CRP,
rs = 0.59, p< 0.01; ECP, rs = 0.63, p< 0.01, respectively)
but, signiﬁcant negative correlations with ACT (hs-CRP,
rs = 0.53, p< 0.05; ECP, rs = 0.62, p< 0.01, respec-
tively) and FEV1 % (hs-CRP, rs = 0.46, p< 0.05; ECP,
rs = -0.57, p< 0.01, respectively). As regards CE, a signiﬁcant
positive correlation was seen with serum ECP (rs = 0.49,
p< 0.05) but, not with serum hs-CRP (rs = 0.39, p> 0.05)
in all asthmatic patients.
Table 5 shows descriptive and comparative statistics of all
investigations in asthmatic patients (5 out of each asthmatic
subgroup) before and after therapy. Serum ECP and hs-CRP
levels showed a signiﬁcant fall (p< 0.01and p< 0.05, respec-
tively), while, FEV1 % and ACT showed a signiﬁcant increase
(p< 0.05) but, CE and serum total IgE showed no signiﬁcant
change in the subgroup of asthmatic patients (n= 15) who
were followed up after 2 months of asthma therapy.
Fig. 1 shows the receiver operating characteristic curve
(ROC) applied to assess the diagnostic utility of ECP in
discriminating moderate from severe asthma patients. The best
diagnostic cutoff for ECP was 11.5 lg/L. This had a diagnostic
sensitivity of 86.7%, speciﬁcity 60%, negative predictive value
60%, positive predictive value 86.7% and efﬁciency 80%. Area
under the curve (AUC) was 0.682.
Discussion
Asthma is a widespread chronic disease. Its subjective and eco-
nomic aspects require development of objective methods for
the assessment of the disease activity, treatment efﬁcacy,
and, if possible, prevention of attacks [8]. For diagnostic and
prognostic purposes some conventional markers are being
Table 3 Statistical comparison of serum ECP among different
studied groups.
Groups z p
Control vs. all asthmatic patients 3.9 <0.01
Control vs. mild asthma patients 2.97 <0.05
Control vs. moderate asthma patients 1.9 <0.05
Control vs. severe asthma patients 4.19 <0.01
Mild asthma patients vs. moderate asthma patients 0.53 <0.01
Mild asthma patients vs. severe asthma patients 2.77 <0.01
Moderate asthma patients vs. severe asthma patients 2.86 <0.01
ECP, eosinophilic cationic protein.
Table 1 Demographic, clinical and laboratory data among all studied population.
Parameter Control group (n= 20)
mean ± SD/median (IQR)
All asthmatics (n= 30)
mean ± SD/median (IQR)
t (z*) p
Age (years) 32.6 ± 14.1 33 ± 12.5 0.12 >0.05
Sex: M/F 14/16 12/18 X2 = 0.08a >0.05
BMI (kg/m2) 21 ± 2 22 ± 3 1.5 >0.05
FEV1 % predicted 89.4 ± 9.6 69.5 ± 7.2 5.6 p< 0.01
ACT 25 ± 0 16 ± 4 4.2 p< 0.01
CE count (%) 4 (2–10) 11 (4–32) 2.2* p< 0.05
Serum total IgE (IU/ml) 155 (89–273) 315 (152–425) 2.3* p< 0.05
Serum hs-CRP (ng/L) 2.4 ± 1.7 16.3 ± 10 10.2 p< 0.01
Serum ECP (lg/L) 2.65 ± 0.92 17.7 ± 11.5 11.6 p< 0.01
a Chi square test is used; * Wilcoxon rank sum test is used; M/F, male/female; BMI, body mass index; FEV1, forced expiratory volume in 1 s;
ACT, asthma control test; CE, circulating eosinophil; hs-CRP, high sensitive C-reactive protein; ECP, eosinophilic cationic protein.
Table 2 Statistical comparison of serum hs-CRP among
different studied groups.
Groups z p
Control vs. all asthmatic patients 3.56 <0.01
Control vs. mild asthma patients 2.42 <0.05
Control vs. moderate asthma patients 2.95 <0.01
Control vs. severe asthma patients 4.95 <0.01
Mild asthma patients vs. moderate asthma patients 0.79 <0.05
Mild asthma patients vs. severe asthma patients 3.62 <0.01
Moderate asthma patients vs. severe asthma patients 3.08 <0.01
Hs-CRP, high sensitive C-reactive protein.
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FEV1 % predicted, CE count, serum IgE level etc. Now, it has
been suggested that eosinophil may contribute to airway
hyperresponsiveness in asthma through the effects of eosino-
phil derived granular proteins on the bronchial epithelium
such as ECP, major basic protein (MBP), eosinophil peroxi-
dase (EPO) and eosinophil derivative neurotoxin (EDN) [12].
In asthma, the importance of airway inﬂammation has been
well established. Besides the airway inﬂammation, systemic
inﬂammation may also exist in asthma. The relevance of high
sensitivity assays for hs-CRP, which is known to be a sensitive
marker of low-grade systemic inﬂammation, has not been fully
studied in asthma. Studies have attempted to validate the use
of hs-CRP as a surrogate marker of airway inﬂammation in
bronchial asthma [13].The present work aimed to study the clinical utility of bio-
logical markers hs-CRP and ECP for severity classiﬁcation of
asthma and follow up therapy.
The results of this study showed that serum ECP, serum hs-
CRP, serum total IgE and CE were signiﬁcantly higher
(p< 0.01,0.01, 0.05 and 0.05, respectively), while FEV1 %
and ACT were signiﬁcantly lower (p< 0.01) in asthmatic
patients compared to the control group. Our results agreed
with those of Zedan et al. [6], Takemura et al. [13] and Kilic
et al. [14]. Such results illustrate the importance of airway
inﬂammation in asthma and support the hypothesis that beside
the airway inﬂammation, systemic inﬂammation may also exist
in patients with bronchial asthma.
Our study revealed that serum hs-CRP levels were signiﬁ-
cantly higher in all asthmatic subgroups; group I (mild
asthma); group II (moderate asthma) and group III (severe
asthma) compared to the control group (p< 0.05, 0.01 and
0.01, respectively). In addition, serum hs-CRP levels were sig-
niﬁcantly higher in group III compared to group I and group
II (p< 0.01) and in group II compared to group I (p< 0.05).
Also, serum hs-CRP showed signiﬁcant positive correlation
with asthma severity and signiﬁcant negative correlation with
ACT and FEV1 % of predicted in all studied asthmatic
patients. These results are in accordance with Takemura
et al. [13], Kilic et al. [14] and Qian et al. [15] who explained
that inﬂammatory process differs with staging of asthma after
the exclusion of the role of infection. The severity of the dis-
ease signiﬁcantly relies on the volume of the bronchial inﬂam-
mation and the amount of inﬂammatory mediators released in
circulation and hence the acute phase reactant will be synthe-
sized by the liver, CRP is one of the most important acute
phase reactants.
The relationship between the levels of hs-CRP and the
severity of asthma indicates that CRP is a proinﬂammatory
agent [14]. Different proinﬂammatory cytokines such as inter-
leukin-1b (IL-1b), IL-6, IL-8 and IL-18 have been synthesized
by the activated protein hs-CRP. These cytokines are increased
due to asthmatic inﬂammation [16,17]. Severity of asthma cor-
relates positively with asthmatic inﬂammation [18].
Our study demonstrated that serum ECP levels were signif-
icantly higher in all asthmatic subgroups; group I; group II
and group III compared to the control group (p< 0.05, 0.05
and 0.01, respectively). Moreover, serum ECP levels were
Table 4 Correlation analysis of serum levels of hs-CRP and ECP against different studied parameters in all asthmatic patients
(n= 30).
Parameter Serum hs-CRP (ng/L) Serum ECP (lg/L)
rs p rs p
Asthma severity 0.59 <0.01 0.63 <0.01
CE count (%) 0.39 >0.05 0.49 <0.05
ACT 0.53 <0.05 0.62 <0.01
FEV1 % predicted 0.46 <0.05 0.57 <0.01
Serum hs-CRP (ng/L) ........... ............ 0.67 <0.01
FEV1, forced expiratory volume in 1s; ACT, asthma control test; CE: circulating eosinophil; hs-CRP, high sensitive C-reactive protein; ECP,
eosinophilic cationic protein.
Table 5 Descriptive and comparative statistics of all investigations in asthmatic patients before and after therapy.
Parameter Before therapy (n= 15)
mean ± SD/median (IQR)
After therapy (n= 15)
mean ± SD/median (IQR)
p
FEV1 % predicted 72 ± 7 81 ± 8.6 p< 0.05
ACT 17 ± 3 20 ± 4 p< 0.05
CE count (%) 12 (1–22) 11 (2–19) p> 0.05
Serum total IgE (IU/ml) 155 (56–221) 135 (44–198) p> 0.05
Serum hs-CRP (ng/L) 18.9 ± 6.8 12.4 ± 5.4 p< 0.05
Serum ECP (lg/L) 22.4 ± 8.7 4.9 ± 2.3 p< 0.01
FEV1, forced expiratory volume in 1 s; ACT, asthma control test; CE: circulating eosinophil; hs-CRP, high sensitive C-reactive protein; ECP,
eosinophilic cationic protein.
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Figure 1 ROC curve analysis showing the diagnostic perfor-
mance of serum ECP for discriminating moderate asthma from
severe asthma.
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group II and in group II compared to group I (p< 0.01,
respectively). Also, serum ECP showed signiﬁcant positive cor-
relation with asthma severity and CE but, signiﬁcant negative
correlation with ACT and FEV1 % of predicted in all studied
asthmatic patients. These results are in accordance with Hosh-
ino and Nakamura [19], Koh et al. [20] and Badar et al. [21].
Zedan et al. [6] and Begum et al. [22] explained that serum
ECP is now accepted as an indicator of eosinophil activity. It
appears to be the earliest indicator of allergen induced bron-
chial inﬂammation when changes in symptoms or in bronchial
responsiveness are not yet evident.In accordance with the previous reports [8,22], the current
work showed that serum ECP levels had signiﬁcantly fallen
(p< 0.01), while, FEV1 % and ACT had signiﬁcantly
increased (p< 0.05) in the subgroup of asthmatic patients
who were followed up after 2 months of asthma therapy.
Begum et al. [22] explained that elevated ECP seems to denote
patients at the risk of inﬂammatory exacerbations, resulting in
practical implications for the therapeutic management of
chronic asthma. ECP is a guide to tail down inhaled corticoste-
roid therapy and assessment of compliance to most forms of
anti-inﬂammatory therapies in asthma and guiding the taper-
ing of inhaled corticosteroid in stabilized asthmatics. Spiro-
metric measurements (FEV1) may not accurately reﬂect the
extent of the inﬂammatory process in the airways and thereby
do not always indicate the best choice of monitoring therapy.
Moreover a strong positive correlation was found between
ECP and hs-CRP in all asthmatic patients. This supports the
hypothesis that both are inﬂammatory markers that could
increase in any inﬂammatory condition such as asthma, but
ECP is more speciﬁc for asthma than hs-CRP.
Assessment of the diagnostic performance of ECP revealed
that the best cutoff value for discriminating patients with mod-
erate from patients with severe asthma was 11.5 lg/L. At this
value, serum ECP had a diagnostic sensitivity of 86.7%, spec-
iﬁcity of 60%, negative predictive value of 60%, positive pre-
dictive value of 86.7% and efﬁciency of 80%. This result
needs further validation by larger wide scale future studies.
To our knowledge, this is one of the ﬁrst reports trying to
elucidate the effect of therapy on serum hs-CRP levels in
patients with bronchial asthma. We noticed that serum hs-
CRP levels had signiﬁcantly fallen (p< 0.05) in the subgroup
770 A.E. Sileem et al.of asthmatic patients who were followed up after 2 months of
asthma therapy. Only one previous study by Takemura et al.
[13] did not ﬁnd a signiﬁcant difference in serum hs-CRP levels
between their asthmatic patients who were on inhaled cortico-
steroids (ICS) and healthy controls and reported that the ICS,
which has well characterized anti-inﬂammatory properties,
used in these patients might have reduced serum hs-CRP.
In conclusion, coupling measurements of serum levels of
both ECP and hs-CRP may add a beneﬁt in determining the
severity of asthma and hence, early addressing the step of ther-
apy. Furthermore, objective monitoring of asthma control
using simple easy to measure serum markers could be
achieved. Serum ECP could effectively discriminate moderate
from severe asthmatic patients.
Further study
Establishment of a reference range for serum levels of ECP and
hs-CRP in asthmatic patients and cutoff values for different
disease stages are needed.
Conﬂict of interest
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